How hot spots of genetic variation evolved in human DNA

Phys.org | March 19, 2019

What makes one person different from one another, and how did these differences evolve? A study by University at Buffalo biologists is illuminating one aspect of this complicated question. The research examines hot spots of genetic variation within the human genome, examining the sections of our DNA that are most likely to differ significantly from one person to another. The findings uncover a complex evolutionary history, shedding light on the malleability of human DNA and pointing to just how adaptable—yet delicate—we are as a species. "We have made some headway into understanding how variations in the genome occur," says Omer Gokcumen, Ph.D., assistant professor of biological sciences in the UB College of Arts and Sciences. "Which parts of the genome are protected and conserved through evolution? Which parts are not protected, and why?

Spotlight

Sometimes, analyzing our DNA sequences isn’t quite enough. RNA-Seq is a next-generation sequencing (NGS)-based technique that looks at the RNA transcripts produced from our DNA, allowing us to look into how our genes are expressed. RNA-Seq has shown its worth across many fields, and neuroscience is no exception. In this infographic, we’ll investigate RNA-seq, how it is used in neuroscience, and how it has the potential to advance our understanding of every cell in the brain.

Spotlight

Sometimes, analyzing our DNA sequences isn’t quite enough. RNA-Seq is a next-generation sequencing (NGS)-based technique that looks at the RNA transcripts produced from our DNA, allowing us to look into how our genes are expressed. RNA-Seq has shown its worth across many fields, and neuroscience is no exception. In this infographic, we’ll investigate RNA-seq, how it is used in neuroscience, and how it has the potential to advance our understanding of every cell in the brain.

Related News

INDUSTRIAL IMPACT

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecute the most challenging structure-based drug discovery targets, including G-protein coupled receptors (GPCRs), and deliver discovery assets to ShouTi’s development pipeline. In addition, Basecamp Bio will explore selective partnerships to tackle high value targets pursued by the biopharmaceutical industry. Basecamp Bio is led by Yingli Ma, Ph.D., President, who brings close to 15 years of research, technology, and drug discovery experience including her previous role as general manager of Amgen Shanghai Research Center. Dr. Ma led Amgen’s global structural biology and drug discovery programs in cardiometabolic and inflammatory diseases. “By bringing together our deep expertise in structure-based drug design with leading drug discovery technologies, we aim to create orally-available small molecule medicines against some of the most complex targets including those validated by biologics,” said Dr. Ma. “With all of these breakthrough technologies under one roof, and access to the Shanghai biotech contract research organization ecosystem as a resource, Basecamp Bio has the ability to greatly accelerate the discovery of assets with best-in-class potential.” Basecamp Bio’s technology leverages the power of cryo-electron microscopy, machine learning and X-ray crystallography, as the basis for its molecular designs. The company employs state-of-the-art small molecule hit identification, including DNA encoded library technology and affinity mass spectrometry selections for membrane proteins. This is integrated with cutting-edge computational chemistry and medicinal chemistry along with a matrix of pharmacological assay platforms. ShouTi’s exceptional experience with cell surface receptor signaling and pharmacology will further enable Basecamp Bio to achieve its goal of designing medicines with optimal pharmaceutical properties to address patient needs. “Given the broad potential of the platform and our team’s deep expertise with challenging drug targets, we are excited to deploy Basecamp Bio to both advance our own pipeline and enable early-stage drug discovery partnerships to extend the reach of our leading-edge science,” Melita Sun Jung, Chief Business Officer, ShouTi About ShouTi ShouTi is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company’s cutting-edge technology platform leverages structure-based drug discovery and computational chemistry expertise and enables ShouTi to develop oral small molecule therapeutics for the treatment of various diseases, including those in the metabolic, cardiovascular, and pulmonary therapeutic areas. By leveraging ShouTi’s world-class GPCR know-how, the company aims to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies targeting this family of receptors.

Read More

AI

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

BioMarin | November 18, 2020

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elite alternative to get Deep Genomics' privileges to each program for development and commercialization. The organizations didn't uncover financial terms. In the cooperation, Deep Genomics will utilize its AI Workbench to recognize and approve target components and lead competitors, and BioMarin will propel them into preclinical and clinical development. The AI Workbench empowers quick investigation of novel targetable components and restorative up-and-comers. It joins deep learning, automation, progressed biomedical information and huge measures of in vitro and in vivo information to precisely recognize targetable sub-atomic systems and guide the revelation and advancement of oligonucleotide treatments.

Read More

MEDICAL

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Be Bio | May 20, 2022

Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline. Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform is harnessing the power of the human B cell to create a new class of autologous and allogeneic cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning. The two companies are investing to drive innovation and reliability in cell therapy manufacturing, a critical success factor for broad and meaningful patient impact. As part of this unique partnership, Resilience will dedicate personnel solely to produce and supply Good Manufacturing Practices (GMP)-grade viral vector and cell therapy drug product for the initial programs in Be Bio’s rare disease pipeline. Through a creative cost and risk-sharing model, Resilience will be responsible for manufacturing costs and receive potential future milestones and royalties. Over the past year, Be Bio has built a strong foundation with our BeCM platform, pipeline, team, and recent $130 million financing. Manufacturing is critical to rapidly progress our BeCMs to the clinic and we have built non-GMP manufacturing capabilities in our Cambridge facility. This deal allows us to drive GMP manufacturing with an outstanding partner, and in a capital efficient manner, Resilience’s broad manufacturing capabilities, strong collaborative spirit and dedicated resources to our platform, make them an ideal partner for our BeCM programs.” Joanne Smith-Farrell, Ph.D., Chief Executive Officer at Be Bio. Resilience will lead clinical GMP manufacturing of both the viral vector and the cell therapy drug product for Be Bio’s initial rare disease programs to support first-in-human clinical trials. Resilience will apply its pioneering bioprocessing solutions and network of cell therapy sites, including facilities in Research Triangle Park, NC, Philadelphia, PA, Waltham, MA and Marlborough, MA to conduct the work. This collaboration shows our excitement for the promising science of Be Bio’s proprietary BeCM platforms, and our confidence in their expertise to deliver transformative cell therapies, By working alongside Be Bio early in the drug development process, we aim to accelerate the development of their B cell medicines with the potential to unlock a pipeline of product candidates across a variety of serious diseases.” Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. About B Cells – A New Class of Cellular Medicines Imagine what could “Be?” In nature, a single B cell engrafts in the bone marrow and can produce thousands of proteins per second at constant levels over decades. B cells are nature’s exquisite medicine factories, manufacturing proteins to fight disease and maintain health. Unleashing the power of B cells is driving a new class of cellular medicines – Engineered B Cell Medicines (BeCM). BeCMs have the potential to be durable, allogeneic, redosable and administered without toxic conditioning. The promise of BeCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas. About Be Biopharma Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb and Takeda Ventures. Since our founding, Be Bio’s investors have committed over $180 million to enable the Company to re-imagine medicine based on the power of B cell therapy. About Resilience Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development.

Read More